Market Cap | 1.78B | P/E | - | EPS this Y | 31.70% | Ern Qtrly Grth | - |
Income | -440.22M | Forward P/E | -4.75 | EPS next Y | 44.20% | 50D Avg Chg | -9.00% |
Sales | 32.77M | PEG | 0.38 | EPS past 5Y | - | 200D Avg Chg | -1.00% |
Dividend | N/A | Price/Book | 2.42 | EPS next 5Y | -19.00% | 52W High Chg | -46.00% |
Recommedations | 1.90 | Quick Ratio | 4.74 | Shares Outstanding | 303.51M | 52W Low Chg | 36.00% |
Insider Own | 0.53% | ROA | -33.35% | Shares Float | 224.41M | Beta | 0.63 |
Inst Own | 87.46% | ROE | -65.36% | Shares Shorted/Prior | 60.29M/59.33M | Price | 7.18 |
Gross Margin | -44.43% | Profit Margin | - | Avg. Volume | 6,016,856 | Target Price | 24.42 |
Oper. Margin | -327.64% | Earnings Date | Oct 30 | Volume | 4,421,887 | Change | -0.14% |
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
HC Wainwright & Co. | Buy | Aug 12, 24 |
Piper Sandler | Neutral | Jul 29, 24 |
HC Wainwright & Co. | Buy | Jun 28, 24 |
JMP Securities | Market Outperform | Jun 20, 24 |
HC Wainwright & Co. | Buy | Jun 3, 24 |
HC Wainwright & Co. | Buy | May 31, 24 |
HC Wainwright & Co. | Buy | May 24, 24 |
HC Wainwright & Co. | Buy | May 10, 24 |
Piper Sandler | Overweight | Mar 14, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Rothbaum Wayne P. | Director Director | Sep 15 | Buy | 5.3 | 5,000,000 | 26,500,000 | 23,067,333 | 09/15/23 |
Rothbaum Wayne P. | Director Director | Dec 02 | Buy | 6.50 | 10,000,000 | 65,000,000 | 18,067,333 | 12/02/22 |
Vogt Frederick G | Interim CEO & Genera.. Interim CEO & General Counsel | Nov 28 | Buy | 5.98 | 1,000 | 5,980 | 2,000 | 11/28/22 |
MCPEAK MERRILL A | Director Director | Nov 28 | Buy | 6.18 | 10,000 | 61,800 | 228,633 | 11/28/22 |
Dukes Iain D. | Director Director | Nov 23 | Buy | 6.10 | 10,000 | 61,000 | 22,000 | 11/28/22 |
MCPEAK MERRILL A | Director Director | May 31 | Buy | 6.82 | 20,000 | 136,400 | 218,633 | 06/02/22 |
Maynard Ryan D | Director Director | May 31 | Buy | 6.745 | 7,500 | 50,588 | 7,500 | 06/02/22 |
WEISER MICHAEL | Director Director | May 31 | Buy | 6.8 | 10,000 | 68,000 | 112,632 | 06/02/22 |
Vogt Frederick G | Interim CEO & Genera.. Interim CEO & General Counsel | Jun 01 | Buy | 6.44 | 1,000 | 6,440 | 1,000 | 06/02/22 |
Rothbaum Wayne P. | Director Director | May 31 | Buy | 6.6 | 1,000,000 | 6,600,000 | 8,067,333 | 06/02/22 |